Teacher Retirement System of Texas Sells 33,061 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Teacher Retirement System of Texas cut its Gilead stake by 9.9% in Q4, selling 33,061 shares and now holding 299,498 shares valued at $36.76 million.
• Gilead beat Q4 estimates with $1.86 EPS vs. $1.83 and $7.93B revenue (up 4.7% YoY), set FY2026 guidance of $8.45–8.85 EPS, and carries an average analyst target of $157.35 (consensus: Moderate Buy).
• Insiders have been selling recently — CEO Daniel O'Day sold 115,640 shares (~$17.35M) and insiders sold 178,640 shares in the last three months — while the company raised its quarterly dividend to $0.82 (annual $3.28, ~2.5% yield).

Teacher Retirement System of Texas cut its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 299,498 shares of the biopharmaceutical company's stock after selling 33,061 shares during the quarter. Teacher Retirement System of Texas' holdings in Gilead Sciences were worth $36,760,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Mystic Asset Management Inc. bought a new position in Gilead Sciences in the fourth quarter valued at about $206,000. West Michigan Advisors LLC raised its position in Gilead Sciences by 18.5% in the fourth quarter. West Michigan Advisors LLC now owns 26,705 shares of the biopharmaceutical company's stock valued at $3,278,000 after purchasing an additional 4,173 shares during the last quarter. Meadow Creek Wealth Advisors LLC raised its position in Gilead Sciences by 14.3% in the fourth quarter. Meadow Creek Wealth Advisors LLC now owns 2,210 shares of the biopharmaceutical company's stock valued at $271,000 after purchasing an additional 276 shares during the last quarter. HB Wealth Management LLC increased its stake in shares of Gilead Sciences by 9.0% in the fourth quarter. HB Wealth Management LLC now owns 51,454 shares of the biopharmaceutical company's stock valued at $6,315,000 after buying an additional 4,266 shares during the period. Finally, Caprock Group LLC increased its stake in shares of Gilead Sciences by 20.1% in the fourth quarter. Caprock Group LLC now owns 76,931 shares of the biopharmaceutical company's stock valued at $9,443,000 after buying an additional 12,895 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Up 0.6%

GILD stock opened at $133.64 on Friday. The stock's 50 day simple moving average is $142.93 and its 200 day simple moving average is $131.90. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company has a market cap of $165.88 billion, a P/E ratio of 19.74, a price-to-earnings-growth ratio of 1.76 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the prior year, the business earned $1.90 EPS. The firm's revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 8.63 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were paid a dividend of $0.82 per share. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences's dividend payout ratio (DPR) is currently 48.45%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wolfe Research increased their price target on Gilead Sciences from $155.00 to $170.00 and gave the company an "outperform" rating in a research note on Thursday, February 12th. Weiss Ratings reissued a "buy (b)" rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. The Goldman Sachs Group increased their price target on Gilead Sciences from $125.00 to $130.00 and gave the company a "neutral" rating in a research note on Friday, April 17th. Scotiabank increased their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a "sector outperform" rating in a research note on Wednesday, February 11th. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $150.00 to $165.00 and gave the company an "overweight" rating in a research note on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $157.35.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 115,640 shares of the business's stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the sale, the chief executive officer directly owned 613,912 shares of the company's stock, valued at approximately $92,086,800. The trade was a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the chief financial officer directly owned 176,191 shares of the company's stock, valued at $24,835,883.36. This represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 178,640 shares of company stock valued at $26,691,550. 0.30% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.